A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Non-Carriers

The PI of this project was:

This project was funded by: Wyeth/Pfizer Pharmaceuticals

The term of this project was: August 2011 to December 2015

The number of subjects scanned during this project was: 5